| Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis R Longo, P Pollesello, C Ricci, F Masutti, BJ Kvam, L Bercich, LS Croce, ... Journal of Magnetic Resonance Imaging 5 (3), 281-285, 1995 | 501 | 1995 |
| Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan Z Papp, I Édes, S Fruhwald, SG De Hert, M Salmenperä, H Leppikangas, ... International journal of cardiology 159 (2), 82-87, 2012 | 410 | 2012 |
| Noninvasive in vivo quantitative assessment of fat content in human liver C Ricci, R Longo, E Gioulis, M Bosco, P Pollesello, F Masutti, LS Crocè, ... Journal of hepatology 27 (1), 108-113, 1997 | 410 | 1997 |
| Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe, and proton nuclear magnetic resonance study. P Pollesello, M Ovaska, J Kaivola, C Tilgmann, K Lundström, N Kalkkinen, ... Journal of Biological Chemistry 269 (46), 28584-28590, 1994 | 312 | 1994 |
| Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure … RA de Boer, G De Keulenaer, J Bauersachs, D Brutsaert, JG Cleland, ... European journal of heart failure 21 (3), 272-285, 2019 | 293 | 2019 |
| Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure … C Maack, M Lehrke, J Backs, FR Heinzel, JS Hulot, N Marx, WJ Paulus, ... European heart journal 39 (48), 4243-4254, 2018 | 270 | 2018 |
| Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels P Kaheinen, P Pollesello, J Levijoki, H Haikala Journal of cardiovascular pharmacology 37 (4), 367-374, 2001 | 248 | 2001 |
| Levosimendan: current data, clinical use and future development MS Nieminen, S Fruhwald, LMA Heunks, PK Suominen, AC Gordon, ... Heart, lung and vessels 5 (4), 227, 2013 | 229 | 2013 |
| The patient perspective: quality of life in advanced heart failure with frequent hospitalisations MS Nieminen, K Dickstein, C Fonseca, JM Serrano, J Parissis, F Fedele, ... International journal of cardiology 191, 256-264, 2015 | 200 | 2015 |
| Binding of levosimendan, a calcium sensitizer, to cardiac troponin C T Sorsa, S Heikkinen, MB Abbott, E Abusamhadneh, T Laakso, ... Journal of biological chemistry 276 (12), 9337-9343, 2001 | 194 | 2001 |
| Pharmacological mechanisms contributing to the clinical efficacy of levosimendan Z Papp, K Csapó, P Pollesello, H Haikala, I Édes Cardiovascular drug reviews 23 (1), 71-98, 2005 | 190 | 2005 |
| Biochemical and immunohistochemical evidence that in cartilage an alkaline phosphatase is a Ca2+-binding glycoprotein. B de Bernard, P Bianco, E Bonucci, M Costantini, GC Lunazzi, ... The Journal of cell biology 103 (4), 1615-1623, 1986 | 189 | 1986 |
| Levosimendan is a mitochondrial KATP channel opener DM Kopustinskiene, P Pollesello, NEL Saris European journal of pharmacology 428 (3), 311-314, 2001 | 187 | 2001 |
| The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig S Szilágyi, P Pollesello, J Levijoki, P Kaheinen, H Haikala, I Édes, Z Papp European journal of pharmacology 486 (1), 67-74, 2004 | 172 | 2004 |
| A role for the RISK pathway and KATP channels in pre‐ and post‐conditioning induced by levosimendan in the isolated guinea pig heart EF Du Toit, A Genis, LH Opie, P Pollesello, A Lochner British journal of pharmacology 154 (1), 41-50, 2008 | 169 | 2008 |
| Potassium-specific effects of levosimendan on heart mitochondria DM Kopustinskiene, P Pollesello, NEL Saris Biochemical pharmacology 68 (5), 807-812, 2004 | 163 | 2004 |
| The cardioprotective effects of levosimendan: preclinical and clinical evidence P Pollesello, Z Papp Journal of cardiovascular pharmacology 50 (3), 257-263, 2007 | 157 | 2007 |
| Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use Z Papp, P Agostoni, J Alvarez, D Bettex, S Bouchez, D Brito, V Černý, ... Journal of cardiovascular pharmacology 76 (1), 4-22, 2020 | 155 | 2020 |
| Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper D Farmakis, J Alvarez, TB Gal, D Brito, F Fedele, C Fonseca, AC Gordon, ... International Journal of Cardiology 222, 303-312, 2016 | 154 | 2016 |
| The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure … M Van Bilsen, HC Patel, J Bauersachs, M Boehm, M Borggrefe, ... European journal of heart failure 19 (11), 1361-1378, 2017 | 153 | 2017 |
Zoltán PappUniversity of Debrecen, Department of Cardiology, Division of Clinical Physiologyایمیل تأیید شده در med.unideb.hu